| WARF: P98010US |  |
| Method of Locking 1 Alpha-OH of Vitamin D Compounds in Axial Orientation |
| INVENTORS | • | Hector DeLuca, Rafal Sicinski |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a novel method of modifying the structure of a vitamin D analog to increase its activity.
OVERVIEW
The conformational behavior of vitamin D can play an important role in its biologic activity. Vitamin D compounds can exist as a mixture of two A-ring chair conformers, alpha and beta, which are in dynamic equilibrium. Those vitamin D analogs substituted in the A-ring with a 1alpha-hydroxy (OH) group, the active moiety, have a 1alpha-OH orientation that is axial in the alpha chair form. The need exists for vitamin D compounds having structures that exhibit certain orientations.
THE INVENTION
UW-Madison researchers have developed a novel method of modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its biologic activity. The method involves altering the conformational equilibrium of the A-ring of the 1alpha-hydroxylated vitamin D compound to favor a chair conformation that presents the 1alpha-OH in the axial orientation. Compounds presenting the 1alpha-OH in the axial orientation provide the greatest in vivo biologic response and are well–suited for treatment of a variety of disorders.
APPLICATIONS
- Treatment of disorders from cancer to osteoporosis
KEY BENEFITS
- This method of “locking” constituents in prominent orientations can be applied to a wide range of compounds.
- These vitamin D compounds may have a wide variety of biologic activities.
- As a result of their preferential calcemic activity, these compounds may be used in the treatment of metabolic bone disease where bone loss is a major concern, as in osteoporosis.
- May also provide a method of treating female infertility in mammals
- Especially suited for treatment and prophylaxis of human disorders that are characterized by an imbalance in the immune system, as in multiple sclerosis
- Effective in treating a variety of disorders, such as cancer and psoriasis, which are characterized by proliferation of undifferentiated cells
- May be used to treat rickets and vitamin D rickets
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
